Clinical trials: Hepatitis, Viral, Human
HCC in Chronic HCV Patients With Advanced Liver Fibrosis
Clinical Impacts of Achieving SVR in Patients With Advanced Hepatic Fibrosis Related to Chronic HCV Treated With Direct Acting Antivirals
Chronic HCV infection has relatively slow rate of progression. Liver fibrosis is the main sequlae and usually progressed to cirrhosis after long period (10 to 20 years) [6].
- Trial name
- NCT03884062
- Testing
- DAAs
- Volunteers
- 3,000 people
- Sponsor
- Egyptian Liver Hospital
Hepatitis C, Chronic
REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy
This 4 arm study is designed for patients with CHC who have not responded to peginterferon alfa-2b (12KD)/ribavirin combination therapy.
- Trial name
- NCT00087646
- Testing
- Ribavirin, peginterferon alfa-2a [Pegasys]
- Where
- 104 sites in United States, Belgium and 12 more
- Volunteers
- 948 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis B
Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents
Current treatment guidelines indicate that oral antiviral agents for HBeAg-positive chronic hepatitis B virus infection (CHB) can be stopped if the patient has undergone HBeAg seroconversion with HBV-DNA loss measured at two…
- Trial name
- NCT02337127
- Testing
- Lamivudine
- Where
- Taiwan
- Volunteers
- 500 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Hepatitis Delta Virus
Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV
The Phase 3 LIMT-2 study will evaluate the safety and efficacy of Peginterferon Lambda treatment for 48 weeks with 24 weeks follow-up compared to no treatment for 12 weeks in patients chronically infected with HDV.
- Trial name
- LIMT-2 (NCT05070364)
- Testing
- Peginterferon Lambda-1a
- Where
- 48 sites in United States, Belgium and 10 more
- Volunteers
- 150 people
- Sponsor
- Eiger BioPharmaceuticals
Hepatitis C
Study of the Immune Response to Hepatitis C Virus
The purpose of this study is to investigate the mechanism of a successful immune response to hepatitis C virus (HCV) infection. Currently, it is believed that the immune system is involved in responding to HCV infection, but how…
- Trial name
- NCT00237432
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Rockefeller University
Hepatitis C
Reinfection and Long Term Outcomes in Intravenous Drug Users (IVDUs) After Hepatitis C Treatment
The investigators will identify possible participants using our database of previously treated hepatitis c patients. The investigators will identify those who have documented evidence of current injecting drug use as a risk…
- Trial name
- NCT01329952
- Where
- United Kingdom
- Volunteers
- 90 people
- Sponsor
- Pennine Acute Hospitals NHS Trust
Hepatitis B, Chronic, Fibrosis, Liver
Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 Diabetes
An exploratory comparison of changes in liver fibrosis through glycemic control within and between groups after administration of Pioglitazone and Evogliptin in chronic hepatitis B patients with type 2 diabetes and liver fibrosis
- Conditions
- Hepatitis B, Chronic, Fibrosis, Liver, Diabetes Mellitus, Type 2
- Trial name
- NCT05473806
- Testing
- Pioglitazone 15 Mg Oral Tablet, Evogliptin 5mg
- Where
- 4 sites in South Korea
- Volunteers
- 28 people
- Sponsor
- Seung Up Kim
Hepatitis C, Chronic
Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir
A single-arm, single-center, open label Phase 1 study of a 12-week course of Sofosbuvir (SOF)/Velpatasvir (VEL) in 10 HCV-infected pregnant women 1 that will evaluate the plasma pharmacokinetic parameters of SOF/VEL administered…
- Trial name
- NCT04382404
- Testing
- Sofosbuvir-Velpatasvir Drug Combination
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Catherine Anne Chappell
Hepatitis B
Tenofovir Disoproxil Fumarate (Tenofovir DF) Versus Emtricitabine/Tenofovir DF in Subjects Resistant to Lamivudine
The aim of therapy for the treatment of chronic hepatitis B virus (HBV) is to maintain suppression of viral replication to prevent the emergence of complications, which requires long-term therapy.
- Trial name
- NCT00737568
- Testing
- TDF, FTC/TDF
- Where
- 69 sites in United States, Austria and 12 more
- Volunteers
- 280 people
- Sponsor
- Gilead Sciences
Treatment of Hepatitis C
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 8 Weeks in Subjects With Chronic Genotype 1 HCV and HIV-1 Co-infection
Target Population: Hepatitis C Treatment Naïve, non-cirrhotic, Chronic genotype 1 hepatitis C virus (HCV) infected adults that are co-infected with human immunodeficiency virus (HIV)-1and have HCV RNA < 6 x106 IU/mL Duration of…
- Trial name
- NCT02480387
- Testing
- Ledipasvir/Sofosbuvir FDC
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Peter J. Ruane, M.D., Inc.
Bacterial Infections, Virus Diseases
Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)
This study will determine whether participants who receive V419 (PR5I) at 2, 4, and 11 to 12 months of age have an acceptable response to the vaccine.
- Trial name
- NCT01480258
- Testing
- PR5I, Rotavirus vaccine, Prevenar 13™
- Volunteers
- 1,315 people, healthy volunteers welcome
- Sponsor
- MCM Vaccines B.V.
Hepatitis C Infection, HIV Infection
A Study to Assess the Safety of HIV and Hep C Vaccine Candidates When Given Separately or in Combination
This study is aimed at assessing the safety of candidate Hepatitis C vaccines AdCh3NSmut/MVA-NSmut and HIV vaccines ChAdV63.HIVconsv/MVA.HIVconsv when administered separately or in combination to healthy volunteers.
- Trial name
- NCT02362217
- Testing
- AdCh3NSmut1, MVA-NSmut, ChAdV63.HIVconsv
- Where
- United Kingdom
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Whole Cell Pertussis, Haemophilus Influenzae Type b
Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m
The purpose of the study is to evaluate the immunogenicity, safety and reactogenicity of a booster dose of DTPw-HBV/Hib-MenAC compared to DTPw-HBV/Hib given to healthy subjects at 15 to 24 months of age primed with 3 doses of…
- Conditions
- Whole Cell Pertussis, Haemophilus Influenzae Type b, Hepatitis B, Diphtheria
- Trial name
- NCT00136604
- Testing
- Tritanrix-HepB/Hib-MenAC, Mencevax ACWY, Tritanrix-HepB/Hiberix
- Where
- 3 sites in Thailand
- Volunteers
- 617 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diphtheria, Tetanus
Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™
The present trial is a follow-up of AL203 study (NCT00343889). Primary Objectives: To describe the antibody persistence at 15 to 18 months of age and the booster effect of a dose of DTaP-HB-PRP~T or Tritanrix-HepB/Hib™ (given…
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT00534833
- Testing
- DTaP-HB-PRP~T vaccine, Tritanrix-HepB/Hib™, Oral Polio Vaccine
- Where
- 2 sites in Philippines
- Volunteers
- 362 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Chronic Hepatitis B
Interferon Alpha 2b Plus Ribavirin for Chronic Hepatitis B
Hepatitis B virus (HBV) causes a wide spectrum of liver diseases, such as fulminant or acute hepatitis, chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma.
- Trial name
- NCT00275938
- Testing
- interferon alpha 2b plus ribavirin
- Volunteers
- 120 people
- Sponsor
- National Taiwan University Hospital
Hepatitis B, Human Immunodeficiency Virus
HBV-HIV Coinfection Research Network
Despite effective ART that can suppress both HIV and HBV, HBV-related liver disease remains a significant co-morbidity in this population.
- Trial name
- NCT01924455
- Where
- 8 sites in United States, Canada
- Volunteers
- 139 people
- Sponsor
- Virginia Commonwealth University
Chronic Hepatitis B
A Phase III Study of Entecavir vs Lamivudine in Chronic Hepatitis B Subjects With Incomplete Response to Lamivudine
The purpose of this clinical research study is to assess the safety and effectiveness of switching to entecavir compared to continued lamivudine in patients with chronic hepatitis B.
- Trial name
- NCT00036608
- Testing
- Entecavir
- Where
- 39 sites in United States
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis C, People Who Inject Drugs
Treatment of HCV-Infected Recent Injection Drug Users in U.S. Liver Clinics
Direct antiviral therapy (standard of care) administered to chronic hepatitis C-infected patients, in two hepatology clinics, who had used intravenous drugs in the past 6 months of signing informed consent (IC).
- Trial name
- NCT05895448
- Testing
- velpatasvir and sofosbuvir once daily for 12 weeks (brand or branded generic) .
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Center For Hepatitis C, Atlanta, GA
Hepatitis C, Chronic
Observational Study in HCV Chronic Infection
HCV infection is the most frequent cause of liver chronic disease, cirrhosis and hepatocellular carcinoma in western countries. To date, the standard antiviral treatment, including pegylated interferon (PEG-IFN) plus ribavirin…
- Trial name
- NCT01945008
- Where
- Italy
- Volunteers
- 7,600 people
- Sponsor
- Istituto Superiore di Sanità
Carcinoma, Hepatocellular, Hepatitis C Virus Infection, Response to Therapy of
Possible Differences in HCC Course Depending on DAA Treatment
BACKGROUND It is estimated that around 71 milion people live with chronic hepatitis C virus (HCV) infection. This may lead to the development of liver cirrhosis and hepatocellular carcinoma (HCC).
- Conditions
- Carcinoma, Hepatocellular, Hepatitis C Virus Infection, Response to Therapy of, Drug Effect, Drug Side Effect
- Trial name
- NCT05376943
- Testing
- Direct Acting Antivirals
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Medical University of Warsaw
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.